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Case presentation
A 40-year-old man has undergone chronic hemodialysis for 7 years.
He had nephrotic syndrome from age 2 to 5 years but was apparently
well until age 18, when proteinuria was detected again. At age 28,
hypertension was noted. Hematocrit was 36%; white blood cell count,
6700/mm3; and creatinine clearance, 69 mI/mm. Chest x-ray and intra-
venous pyelogram were normal. A renal biopsy disclosed chronic
glomerulonephritis.
At age 31, a grade lI/VI holosystolic cardiac murmur was noted.
Hematocrit was 29%; serum creatinine, 9.8 mg/dl; BUN, 83 mg/dl;
phosphate, 5.6 mg/dl; and calcium, 7.2 mg/dl. Calcium carbonate,
aluminum hydroxide, dihydrotachysterol, and folic acid were pre-
scribed. At age 32, his blood pressure was 145/90 mm Hg. The
hematocrit was 20.5%; serum creatinine, 12.1 mg/dl; and BUN, 87
mg/dl. Fluoxymesterone, 40 mg daily, was prescribed. At age 33,
uremic symptoms were evident. The hematocrit was 14%; white blood
cell count, 7000/mm3; serum creatinine, 22 mg/dl; BUN, 140 mg/dl;
serum bicarbonate, 14 mEq/liter; and serum potassium, 4.3 mEq/Iiter.
Serum ferritin was 218 ng/ml. Hepatitis B surface antibody was positive
and hepatitis B antigen negative. A plain chest film showed generalized
cardiomegaly, and an electrocardiogram revealed anterolateral ische-
mia. Two units of red blood cells were transfused and hemodialysis was
begun.
He improved and returned to his home in Alaska to continue chronic
hemodialysis. Because his hematocrit fell repeatedly to levels of
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12%—l4%, he returned to Seattle every 2 to 3 weeks to receive packed
red cell transfusions. Five months after starting dialysis, his blood
pressure was 152/100mm Hg. Stool guaiac was negative. Serum ferritin
was 566 ng/ml. Chest x-ray revealed cardiomegaly. A radioisotope scan
revealed an enlarged spleen and a normal-sized liver. An electrocardio-
gram disclosed left ventricular hypertrophy with good left ventricular
function. Bone-marrow aspiration revealed changes consistent with
anemia of chronic disease. Fluoxymesterone was discontinued and
weekly nandrolone decanoate administration was begun, 100 mg intra-
muscularly. Transfusion requirements did not diminish. Five months
later a plain chest film revealed massive cardiomegaly.
At age 34 (15 months after the patient started hemodialysis), he
received a cadaveric renal transplant. The hematocrit rose within one
month to 27%; white blood cell count rose from 4200 to 7200/mm3; and
platelets rose from 97,000 to 204,000/mm3. Three months following
transplantation, the aliograft was rejected, and treatment with chronic
hemodialysis was resumed. The hematocrit fell to 11%, and frequent
packed red-cell transfusions again were required to stabilize the level at
about 19%. The mean corpuscular volume was 85 fi and reticulocytes
were not detected on a peripheral smear. White blood cell count was
1900/mm3 and platelet count, 46,000/mm3. Bleeding time was 5 minutes
and prothrombin and fibrinogen levels were normal. Serum aluminum
was 11 g/1iter. Another bone-marrow aspiration disclosed normal
erythroid, granulocyte, and megakaryocyte maturation, increased iron
deposition in reticuloendothelial cells, and normal sideroblasts. The
spleen tip was 3 cm below the left costal margin, and the liver edge was
4 cm below the right costal margin. A splenic red-cell-sequestration
study employing 51Cr-labeled red cells detected no significant splenic
entrapment. Two years after hemodialysis was resumed, the serum
ferritin was 5457 ng/ml. Deferoxamine, 1.0 g intramuscularly 6 hours
before each hemodialysis, was begun and was continued for the
subsequent 2 years. Although he worked 7 days a week running his
country store, his energy and "wind" would "give out" by early
afternoon and he would rest the remainder of the day. He could no
longer unload the supplies delivered to his store.
By age 39, he had received a total of 313 units of red blood cells. The
serum contained HIV antibody. At that time, recombinant human
erythropoietin (rHuEpo) was given in an initial dose of 300 units/kg
intravenously and was continued three times per week. Baseline
hematocrit was 19%; white blood cell count, 2900/mm3; platelets,
87,000/mm3; and reticulocytes, 32,000/mm3. Serum iron was 196 g/dl;
iron binding capacity, 209 g/dl; transferrin saturation, 94%; and serum
ferritin, 4444 ng/ml. Daily medications were folic acid, multivitamins B
and C, digoxin, atenolol, minoxidil, nifedipine, and aluminum hydrox-
ide. On physical examination he was deeply pigmented. The blood
pressure was 158/90 mm Hg; a grade Ill/VI systolic murmur was heard
at the apex, and a Il/VI systolic murmur was heard at the pulmonic
area; the point of maximum cardiac impulse was at the left anterior
axillary line. The lungs were clear to auscultation, and the peripheral
pulses were intact. The spleen tip was palpated two fingerbreadths
below the left costal margin, and the liver edge was three fingerbreadths
below the right costal margin. The transplanted kidney was palpated in
the left lower abdominal quadrant and was small and nontender.
Within 8 weeks after initiation of rHuEpo therapy, his hematocrit was
38%; no transfusions had been administered over this time (Fig. 1).
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Fig. 1. Hematocrit and reticulocyte response of patient before and after
receiving recombinant human erythropoietin (rHuEpo).
Clinical improvement was dramatic; he was able to play handball and to
meet all the physical demands of running his country store. This
included working a full day without becoming exhausted, and now
being able to unload the heavy boxes of supplies delivered to his store.
After one year of rHuEpo therapy (75 units/kg, 3 times/week, intrave-
nously), the hematocrit was 36%; mean corpuscular volume, 96 fi; white
blood cell count, 2800/mm3; and platelet count, 82,000/mm3. Serum iron
was 165 g/dl; total iron binding capacity, 183 g/dl; transferrin
saturation, 90%; and serum ferritin, 4005 nglliter. The skin remained
deeply pigmented, the liver was only one fingerbreadth below the right
costal margin, and the spleen was two to three fingerbreadths below the
left costal margin. A plain chest film disclosed that the transverse
cardiac silhouette had decreased from 21.0 to 17.5 cm (Fig. 2). An
electrocardiogram showed a return towards normal voltage. He contin-
ues to enjoy an active life.
Discussion
DR. JOSEPH W. ESCHBACH (Clinical Professor of Nephrol-
ogy, University of Washington School of Medicine, Seattle,
Washington): The association of anemia with renal failure was
first documented by Richard Bright more than 150 years ago.
The nature of this anemia was poorly understood, however,
until 30 years ago, when Erslev proved that erythropoietin
(Epo) was the hormone that regulates erythropoiesis [1], and
Jacobson et a! demonstrated that Epo originated in the kidney
[2]. The anemia previously was thought to be due to the effects
of uremia, because the degree of elevation of blood urea
nitrogen was roughly proportional to the degree of anemia [31.
Naets and Heuse [4] and others [5—7] showed that plasma Epo
levels, measured by the hypoxemic mouse bioassay, were
lower in renal failure than in other anemic conditions, and
concluded that the anemia was related to Epo deficiency. This
conclusion was not totally accepted, in part because multiple
in-vitro marrow culture studies over the past 30 years had
indicated that uremic serum inhibits erythroid function despite
the addition of Epo [8—14]. Only rarely, however, did the
anemia improve with initiation of hemodialysis. When it did
improve in dialysis patients, it did so either spontaneously [15],
after elimination of transfusions [16], or following androgen
therapy (which stimulates Epo production) [17—20]. The wors-
ening of anemia observed after bilateral nephrectomy [21]
indicated that even small amounts of Epo can be produced by
the damaged kidney.
The modern age was ushered in in 1977 when Miyake and
colleagues purified human urinary Epo [221. This landmark
event made it possible for Lin et al [231 and Jacobs et al [24] to
isolate and clone the gene for human Epo. Because of these
advances, we now have a better way of studying and under-
standing the pathophysiology of the anemia of chronic renal
failure, as well as a means by which to correct it [25—29].
The anemia of chronic renal failure probably has more
clinical significance than was previously recognized. Of the
almost 100,000 patients on maintenance dialysis in the United
States, almost all are anemic; only about 3% have a normal
hematocrit [301. Moreover, the anemia can be severe, with
hematocrit levels as low as 11%, even though most dialysis
patients have hematocrit levels between 20% and 30%. Despite
biochemical control of uremia by thrice-weekly dialysis, only
33% of these patients are rehabilitated [311. A major reason for
the lack of rehabilitation has been fatigue induced by anemia
[32].
The diagnosis of the hypoproliferative anemia of uncompli-
cated chronic renal disease is based on the following character-
istics: the red cells are normochromic and normocytic; the
reticulocyte count, when corrected for the degree of anemia, is
usually less than two times normal [33]; the circulating red cells
are often irregular in shape (the "burr cell" [34]); the erythroid:
granulocyte ratio in the bone marrow is slightly decreased or
normal [3]; renal insufficiency is present (as defined by a serum
creatinine above 2—3 mgldl); and serum erythropoietin levels,
measured by radioimmunoassay, are generally within the nor-
mal range [35—37]. Obviously, other causes of hypoproliferative
anemia, such as early-mild iron deficiency and inflammation,
must be excluded.
The anemia of chronic renal failure results in more disabling
symptoms than was previously appreciated [38]. Approxi-
mately 25% of U.S. dialysis patients receive episodic to regular
red-cell transfusions to reduce symptomatic tissue hypoxia.
The manifestations of the anemia of chronic renal failure are
probably no different than those associated with other severe,
chronic anemias; however, because individuals with anemias of
other causes do not remain anemic, or do not remain under
observation as long as the typical dialysis patient does, most
nephrologists believe that the symptoms of anemia consist only
of fatigue, increasing angina, shortness of breath, or other
obvious signs of organ hypoxia. Having the ability to improve
the anemia acutely with rHuEpo has afforded us an opportunity
to assess more reliably those tissue or organ systems that are
adversely affected by the hypoxemia of anemia. Generalized
coldness or a Raynaud's-like condition is present and reverses
with correction of the anemia [27]. Several central-nervous-
system-related disorders improve with correction of the ane-
mia: anorexia, insomnia, depression, and sexual disinterest and
dysfunction [38]. Neurobehavioral changes improve as well
[39]. Cardiomegaly also develops as a result of the anemia [40].
Figures 2 and 3 show a significant decrease in the size of the
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Fig. 2. Chest x-ray (PA view) before and 9 months after beginning rHuEpo therapy.
heart in the patient under discussion 7 months after the anemia
was corrected with rHuEpo therapy. Cardiomegaly has dimin-
ished in many other rHuEpo-treated patients after near correc-
tion of anemia, as demonstrated by serial chest x-rays [38].
Pat hophysiology
Traditional thinking has ascribed the anemia of chronic renal
failure to four mechanisms: (1) Epo deficiency [32, 41]; (2)
shortened red cell survival [42—44]; (3) retained inhibitors or
toxic metabolites that inhibit erythropoiesis [8—li]; and (4)
blood loss resulting from the qualitative platelet defect present
in uremia [451. Superimposed on these possible mechanisms are
other causes of anemia peculiar to the dialysis patient that might
aggravate the underlying hypoproliferative anemia, as I will
discuss.
Epo deficiency. Epo deficiency is unquestionably a major
mechanism of this anemia. Ninety percent of Epo normally is
made in the kidney, and only 10% is produced in the liver [46].
When renal disease develops, maximum Epo secretion presum-
ably is blunted, even when Epo production is stimulated by
hypoxia caused by anemia or other forms of impaired oxygen
delivery [47]. Erythropoietin stimulates terminal differentiation
of committed erythroid progenitors in the marrow, increases
cellular hemoglobin synthesis, and causes marrow reticulocytes
to shift into the circulation prematurely. The normal response
to anemia is an orderly sequence of Epo production that leads
to increased marrow erythropoiesis. Renal disease usually
disrupts this orderly sequence and results in a submaximal Epo
response to an anemic stimulus. When Epo levels are measured
by the classic biologic assay, which depends on the erythroid
response of an ex-hypoxic rat to injected samples of anemic
sera, the levels often are not detectable, because this assay fails
to measure normal or subnormal levels; this limitation some-
times can be overcome by using concentrated plasma [48]. With
the advent of the newer radioimmunoassay method, which is
based on purified urinary Epo [22, 49], more precise measure-
ments of serum Epo levels are possible and indicate that levels
in patients with chronic renal failure are within the normal range
of 13 to 21 mU/mi (for patients with a normal hematocrit) [35,
37]. It is noteworthy, however, that individuals with normal
renal function and similar degrees of anemia have serum Epo
levels 10 to 100 times these "normal" values [37]. Even
anephric patients have Epo levels that are below normal or in
the lower range of normal [36]. Therefore, relative Epo defi-
ciency is clearly present.
Bone marrow inlzibition. For more than 30 years, investiga-
tors have postulated that inhibitors of erythropoiesis play a
significant causal role in this anemia. If present, such inhibitors
could blunt or even block the effect of Epo. Four lines of
evidence suggest the presence of erythropoietic inhibitors in
patients with chronic renal disease. (1) In-vitro erythropoiesis is
impaired when uremic serum is incubated with murine marrow
cells in the presence of growth factors, including Epo [9]; (2)
levels of bioactive Epo in the plasma of some anemic hemodi-
alysis patients are elevated [48]; (3) infusion of Epo-rich plasma
from a patient with aplastic anemia into several patients with
advanced renal failure and anemia failed to elicit a reticulocy-
tosis [501; and (4) a higher proportion of patients treated with
continuous ambulatory peritoneal dialysis (CAPD) achieve nor-
mal hematocrit levels than do hemodialysis patients [51]. Let us
examine each of these experimental and clinical observations.
The addition of uremic human serum to murine marrow cells
in vitro reduces the Epo-induced proliferation of erythroid
progenitor cells (CFU-E: colony forming unit—erythroid) [9].
Three substances have been incriminated as possible inhibiting
solutes: parathyroid hormone (PTH) [52], spermine [53], and
ribonuclease [54]. The problem with these in-vitro studies, in
my view, is that they lack the controls required to support the
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Fig. 3. Chest x-ray (lateral view) before and 9 months after beginning rHuEpo therapy.
selectivity and specificity of such inhibitors. The crude extract
of the parathyroid gland is inhibitory to both BFU-E (burst
forming unit—erythroid), an earlier progenitor cell line than
CFU-E, and to granulocyte progenitor cells (CFU-GM), and to
in-vitro heme synthesis, but not to CFU-E [52]. However,
purified PTH—either the active N-terminal fragment (amino
acids 1-34), or the intact molecule (amino acids 1-84)—when
added to marrow cells in culture in the presence of Epo, fails to
inhibit in-vitro erythropoiesis [55]. Spermine, although it inhib-
its CFU-E, also inhibits CFU-GM. This finding suggests that its
inhibitory effect is not specific [56]. Also, blood levels of
spermine are not elevated in dialysis patients [57]. Ribonucle-
ase-induced CFU-E inhibition occurs only when pharmacologic
amounts of ribonuclease are added to the culture medium [54].
When mouse, rat, or dog erythroid marrow cells are used in
culture, the uremic inhibition of CFU-E is nonspecific: that is,
in-vitro granulopoiesis and megakaryocytopoiesis both are in-
hibited [58], yet blood concentrations of leukocytes and plate-
lets in patients with chronic renal failure usually are normal. Of
more significance, perhaps, is that when an entirely autologous
in-vitro culture system is employed, we observed no inhibition
of erythroid progenitor cells with uremic sera in the presence of
Epo [59].
What is the significance of occassional increases in serum
Epo levels in the anemic dialysis patient? Using bioassay
results from concentrated serum, Caro et al concluded that
some patients have serum Epo levels 3 to 4 times normal [48].
Because these patients remained anemic, one might conclude
that inhibitors suppressed the erythroid response to the modest
elevations in Epo. However, concomitant quantitation of eryth-
ropoiesis was not analyzed; hence, an isolated elevated serum
Epo level is difficult to interpret. As I noted earlier, one must
realize that serum Epo levels in a person with a similar degree
of anemia but with normal renal function would be 10 to 100
times normal. Investigators who have used the radioimmuno-
assay based on purified human Epo consistently have failed to
document significantly elevated serum Epo levels in anemic
patients during the period of progressive renal failure or during
treatment with chronic dialysis [36, 60].
Essers and colleagues infused Epo-rich plasma from a patient
with aplastic anemia into several patients with renal failure.
Erythroid stimulation, as defined by reticulocytosis, occurred
only in patients with mild elevations of BUN, not in those with
severe azotemia [50]. The number of patients studied was small,
and erythroid function was not quantified (that is, with ferroki-
netics). To address this concern, my colleague, Dr. John
Adamson, and I developed and studied a uremic sheep model,
quantifying the erythroid response to Epo-rich plasma derived
from phenylhydrazine and phlebotomy-treated normal sheep
[611. The erythroid response to identical amounts of Epo (as
measured by the radioimmunoassay) in uremic sheep (some of
which required hemodialysis to remain alive) was similar to that
in normal sheep; in some instances, a given animal served as its
own control [61]. The biologic clearance of Epo was similar in
both the normal and uremic conditions [62]. Therefore, using
the sheep model, we could document neither in-vivo nor
in-vitro inhibition of erythropoiesis by uremic toxins [631.
The final observation that has been used to argue for the
existence of uremic suppression of erythropoiesis is that the
hematocrit of patients beginning CAPD often rises toward
normal [51, 64, 65]. The mechanism for this rise has yet to be
defined. Given that peritoneal membranes are "leakier" than
are conventional hemodialysis membranes, it is tempting to
speculate that higher-molecular-weight uremic erythropoietic
inhibitors are being removed by CAPD; if so, this might explain
why CAPD patients with higher Epo levels have better erythro-
poiesis [51] or have improved Epo production [66]. Unfortu-
nately, such mechanisms do not explain why only about one-
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Fig. 4. Red-cell survival, as quantitated by 51chromium, in anemic
hemodialysis patients.
half of patients on CAPD have a significant rise in hematocrit
and why, of those that do, most are unable to sustain the rise for
more than 18 months [671.
Shortened red-cell survival. As Figure 4 shows, red-cell
hemolysis, although mild, can contribute to the anemia. Red-
cell half-life, however, as quantified by 51chromium labeling,
occasionally is normal. Most radioisotopic studies (using
chromium [68], DF32P [7], or '4C cyanate [69]) confirm the
presence of mild hemolysis. The cause of the hemolysis is not
known. Studies 30 years ago suggested that some intravascular
substance(s) retained in patients with advanced renal failure
shortened red-cell survival; when red cells from a patient with
advanced renal failure are infused into a normal subject, red-
cell life span is restored to normal [42]. Neither hemodialysis
nor peritoneal dialysis significantly improves red-cell survival
[7, 70]. In the presence of normal kidneys, increased Epo
secretion would easily compensate for such a mild degree of
hemolysis.
Bleeding. Significant blood loss occurs in as many as 25% of
patients with progressive renal failure and can contribute to
their anemia [71]. The major reason for this increased bleeding
propensity is the qualitative platelet defect that develops in
azotemic patients [45, 72, 731, accounting for blood loss from
the gastrointestinal tract, within the skin, and from other sites.
Platelet dysfunction prolongs the bleeding time [74] and impairs
platelet aggregation in vitro. Several mechanisms can be in-
voked to explain this platelet dysfunction: decreased platelet
factor 3 activity [75], decreased platelet levels of thromboxane
A2 [76], an increase in prostacyclin (PGI2) (an inhibitor of
platelet aggregation derived from the vascular endothelium)
[76], and suboptimal Factor VIII:von Willebrand complex
activity [77].
Traditional treatments. The usual method of managing this
anemia has been to control it by administering androgens if
minimal or no side effects occur, and to give transfusions if
severe hypoxic symptoms develop. In dialysis patients, 1 mg of
folic acid is given orally daily to offset losses of the vitamin into
the dialysate and therefore to prevent development of a super-
imposed megaloblastic process. Iron is administered either
orally or as iron dextran intravenously to keep the serum
ferritin above 30—50 ng/ml. Acute red-cell injury during dialysis
can be prevented by ensuring that the hemodialysis fluid
delivery system functions properly and that the water supply is
monitored to prevent exposure to chloramine, formaldehyde,
high dialysate temperature, and dialysate hypotonicity.
Administration of androgens can improve the anemia either
by stimulating the erythroid marrow directly or, more likely, by
stimulating renal and/or liver Epo production [18]. Of the
commercially available androgens, only two have been espe-
cially popular, nandrolone decanoate and fluoxymesterone. In a
6-month crossover study with 3 other androgens, nandrolone
decanoate worked the best [20]. Nandrolone decanoate is given
weekly, 100—200 mg intramuscularly, for at least 6 months [19].
If the hematocrit does not rise significantly or if transfusion
requirements continue, a 6-month trial with oral fluoxymester-
one, 10—30 mg/day, might be necessary [17]. Unfortunately,
virilization, liver dysfunction, and other side effects have lim-
ited the use of these agents [78, 79].
Red-cell transfusions have been the fastest way to raise the
hematocrit and therefore reduce or eliminate hypoxic symp-
toms. However, transfusions are associated with significant
risks:
(1) Hepatitis B or non-A, non-B hepatitis are the most
common infections acquired via transfusion. The former now
can be eliminated by proper screening in the blood bank and/or
by immunization. The morbidity and mortality associated with
hepatitis is well known. Transmission of the HIV infection from
transfusions has been documented, and unfortunately it oc-
curred in the patient discussed today. Over the more than 2
years since the appearance of HIV antibodies in this patient, he
has had no obvious clinical effects. Although proper screening
should eliminate the transmission of HIV by transfusion, a
small number of transfused patients probably still will be
exposed [80].
(2) Transfusion-induced HL-A antibodies are a major reason
why some dialysis patients are unable to receive a kidney
transplant.
(3) Erythroid marrow suppression can occur if an indiscrim-
inate, repetitive policy of frequent transfusions is allowed,
particularly if multiple transfusions are given at one time [15].
This patient's erythroid function might have been suppressed
by such a policy, resulting in a continuing need for transfusions.
However, it is difficult not to transfuse a symptomatic, anemic
patient who is thereby able to enjoy a more active, productive
life.
(4) Iron overload can develop easily in the dialysis patient
because intravenous iron, either as iron dextran or red-cell
transfusions, can exceed the body's limited ability to eliminate
iron through fixed gastrointestinal losses, variable menstrual
losses, and procedure-related blood losses [81]. Because the
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serum ferritin is in equilibrium with tissue iron stores [82], a
value of greater than 300 ng/ml indicates iron excess or iron
overload. One unit of blood (that is, 200 ml of red cells)
provides 200 mg of iron; thus, iron excess can easily develop
from multiple transfusions in the absence of significant blood
loss. For every unit of blood transfused, the serum ferritin
increases 60 ng!ml [83]. Our patient had more than 300 transfu-
sions in the absence of obvious significant bleeding, so a serum
ferritin level of 18,000 ng/ml might have been anticipated, yet a
peak value of 5457 ng/ml was noted after about two-thirds of the
transfusions had been received. After approximately one year
of deferoxamine therapy, his serum ferritin level was 4444
nglml; deferoxamine likely was effective in reducing his iron
burden [84]. Iron is initially stored in the reticuloendothelial
cells of the liver, marrow, and other organs and eventually leads
to tissue hemosiderosis, that is, to iron deposition in parenchy-
mal cells. Cellular dysfunction (secondary hemochromatosis)
eventually can occur, but the level of iron stores at which
cellular dysfunction occurs is not clearly established. Histologic
evidence for iron within hepatocytes or myocardial cells does
not necessarily indicate tissue dysfunction. The transfusion of 2
to 3 units of red cells per month for 4 years to non-uremic,
anemic patients, however, resulted in serum ferritin levels as
high as 5000 ng!ml and in evidence of cardiac, liver, and
pancreatic dysfunction [85]. Primary hemochromatosis also is
associated with this pattern of organ dysfunction. Proximal
muscle myopathy has been observed in dialysis patients whose
serum ferritin levels exceed 1000 nglml [86], but this correlation
has not been confirmed [87]; non-cardiac myopathy is an
unusual complication of secondary hemochromatosis [851, and
it is not observed in primary hemochromatosis. Some authors
claim that iron overload occurs with greater frequency in
dialysis patients who inherit at least one of the three "hemo-
chromatosis alleles," HL-A-A3, -B7, or -B14 [86]. Heterozy-
gotes for the gene for primary hemochromatosis do not absorb
iron excessively, however, and intestinal iron absorption is
reduced in iron-overloaded dialysis patients [88]. The patient
under discussion here did not have any of these alleles. He did
have cardiomegaly that probably was related more to the
hypertension and anemia than to the iron overload. He had a
normal blood sugar level and no clinical evidence of myopathy.
The pancytopenia probably was related to a congested spleen,
which in turn might have been related to his history of hepatitis
or to transfusion-induced hemosiderosis [89, 90].
Erythropoietin
Erythropoietin is a glycoprotein secreted by the kidney under
hypoxemic conditions. The intrarenal site of Epo secretion was
identified recently. Several investigators, using in-situ hybrid-
ization techniques, have identified the endothelial cell of the
peritubular capillary in the cortex and outer medulla as the site
[91, 92]. The usual stimulus for Epo production is hypoxia,
caused either by anemia or other forms of impaired oxygen
delivery [47]. For years, intact Epo proved difficult to recover
from the kidney, and various hypotheses were advanced to
explain this: some thought that a pro-Epo was secreted and then
activated to Epo by an alpha globulin in normal plasma [93];
others believed that Epo, like angiotensin, derived from the
activation of a liver-generated Epo precursor by an enzyme
produced in the kidney [94]. These theories were buried when
severely hypoxic rats produced enough Epo to enable the intact
molecule to be recovered from kidney extracts [95]. The actual
cellular mechanisms involved in the stimulation, manufacture,
and release of Epo are not 'et known. We have studied the
pharmacokinetics of Epo in one anephric hemodialysis patient.
The half-life of native Epo (from Epo-rich human plasma) was
6.7 hours, and the half-life of rHuEpo was 7.2 hours. The
half-life of rHuEpo in 5 other hemodialysis patients was approx-
imately 6 to 9 hours [96]. The site of Epo degradation is not
known. The major Epo receptor sites are the erythroid progen-
itor cells. An increase in erythroblast intracellular calcium after
Epo stimulation could be one of the activating mechanisms [97].
Erythropoietin exists in such small quantities in normal blood
or kidney tissue that it has been unrealistic to process it for
therapeutic use. The breakthrough in providing Epo for clinical
use derived from the isolation of the Epo gene from a human
fetal liver genomic library [23, 24, 98]. The cloning strategy
used in isolating this gene was based on the amino acid
sequence information previously derived from small quantities
of the purified urinary protein. Oligonucleotide probes were
constructed and the Epo gene was eventually found in this
genomic library. The gene, along with other nucleic acid
sequences intended to stimulate the expression of Epo, was
spliced into a plasmid expression vector. The nuclei of a
mammalian cell line, the Chinese hamster ovary (CHO) cell,
then were transfected by the Epo-containing plasmid. Use of a
mammalian cell line provides for post-translational glycosyl-
ation of the protein, which is critical for its in-vivo hormonal
activity. The rHuEpo is secreted into the surrounding media
and then purified.
The gene, located on the long arm of chromosome 7 [23], is
organized into five exons and four intervening sequences, or
introns, and exists as a single copy in the human genome [23,
24, 991. The Epo gene encodes a 193-amino acid polypeptide,
the first 27 amino acids of which represent the secretory leader
sequence that is cleaved upon secretion from the cell [23, 24,
99]. An additional post-translational modification is the removal
of the C-terminal amino acid, resulting in a functional protein
containing 165 amino acids and having a molecular weight of
18,400 daltons [23, 24, 99, 100]. The functional protein contains
two internal disulfide bonds between cysteines—one pair at
positions 7 and 161, and the other at positions 29 and 33—and
contains linkages to four carbohydrate chains: three N-linked to
asparagine at the 24th, 38th, and 83rd positions, and an 0-
linkage to serine at the 126th position [101, 102]. The circulating
glycosylated hormone has an apparent molecular weight of
approximately 36,000 daltons as determined by sodium docecyl
sulfate polyacrylamide gel electrophoresis [101]. The rHuEpo is
immunologically and biologically indistinguishable from the
native human urinary Epo, and it is structurally very similar
[101, 102].
The journey from the isolation of the human Epo gene, to
cloning, to animal testing, and to clinical use has been surpris-
ingly fast and remarkably free of serious problems. The gene
was found in 1983 [23], the recombinant hormone was tested in
mice and dogs by the AMGen Corporation in 1984 and 1985
[101, 102], and the first clinical trial in humans on hemodialysis
using AMGen's rHuEpo began in Seattle in December 1985
[26]. A multicenter, phase-Ill clinical trial in the United States
using AMGen's rHuEpo has been in progress since November
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Fig. 5. Changes in serum ferritin levels in 5 hemodialysis patients
treated for one year with rHuEpo. Patient No. 28 did not receive
rHuEpo between weeks 30 to 40.
1986, and a preliminary report confirms the initial study regard-
ing the effectiveness of rHuEpo [29].
Recombinant human erythropoietin has been effective in
virtually all anemic hemodialysis patients in doses of greater
than 50 units/kg, intravenously, three times weekly. Depending
on the dose of rHuEpo, the hematocrit rises at a rate of 1.0
percentage points/week (with 50 units/kg, 3xlwk) to 1.8 percent-
age points/week (with 150 units/kg, 3x/wk). The maintenance
dose required to keep the hematocrit stable at 33—38 has been
25—100 units/kg, 3xlwk, in the majority of patients; approxi-
mately 35% of patients require more than this amount [29].
When enough rHuEpo is given to stimulate erythropoiesis,
iron stores decrease, as evidenced by a fall in serum ferritin.
Serum ferritin levels decreased by more than 50% in 5 iron-
overloaded patients who received rHuEpo for one year (Fig. 5).
Most iron-overloaded patients eventually become iron depleted
because: (1) iron intake ceases (no more transfusions), (2) blood
loss continues via dialyzer blood loss (which will be greater
because there is more hemoglobin per milliliter of blood resid-
ual), and (3) the marrow's need for iron increases. Although
iron overload can be corrected, it remains to be learned whether
functional derangements in iron-congested organs can be re-
versed. Even though the patient under discussion has had a
reduction in iron stores during the past year of rHuEpo therapy,
his platelet count has increased only slightly, the spleen is
slightly smaller, and leukopenia persists. Theoretically, nega-
tive iron balance could be accentuated by periodic phlebotomy
and increased rHuEpo dosage, but no evidence currently exists
that this patient is at risk from hemosiderosis.
The use of rHuEpo in patients with chronic renal failure
(a shortening in the bleeding time) that occurs when the
hematocrit increases to over 30, either by transfusions [103] or
by rHuEpo [104]. Because the degree of uremia is unchanged in
these studies, another factor related to anemia might account
for at least part of the qualitative platelet defect.
The doses of rHuEpo and the schedule of administration used
to correct the anemia (that is, intermittent bolus injections) are
not necessarily physiologic of course. Nevertheless, if uremic
erythropoietic inhibitors exist, they must be of minor impor-
tance, given that they can be overcome so easily. Whether
uremic erythropoietic inhibitors actually do exist could be
determined by quantitative erythroid studies comparing the
response of normal and uremic subjects to rHuEpo. Therefore,
the anemia of chronic renal failure is primarily, if not entirely,
due to erythropoietin deficiency. This anemia should be con-
sidered a hormone deficiency resulting from the inability of the
diseased kidney to produce adequate amounts of Epo.
Other factors can complicate the anemia of chronic renal
failure. These are primarily the result of other aspects of
chronic renal failure or its treatment. These factors also can
interfere with the effectiveness of rHuEpo therapy.
Iron deficiency is most common and has been reviewed
elsewhere [105]. The guidelines for determining relative iron
deficiency, however, must be modified in patients undergoing
rHuEpo therapy. Prior to rHuEpo therapy, the erythroid mar-
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Fig. 6. Red-cell survival, as quantitated by 51chromium, in 8 hemodial-
ysis patients before beginning rHuEpo and more than 6 months after
hematocrit improvement.
might provide newer insights into the significance of the various
proposed mechanisms causing the anemia. Preliminary evi-
100- I I dence in a small number of patients indicates that the mild
0 10 20 30 40 50 60 hemolysis may improve significantly, as quantitated with
Time weeks 51chromium-tagged red cell survival, when the hematocrit has
been maintained at nearly normal levels for many months with
rHuEpo (Fig. 6). Further studies are required to determine
red-cell survival in patients whose anemia has been corrected
fully. Nevertheless, the mild shortening of red-cell survival, in
our experience, does not influence the amount of rHuEpo
required to maintain a stable hematocrit.
The platelet count in patients treated with rHuEpo also has
increased significantly, but not to levels above normal [27, 29].
This slight increase in platelet count, however, is not likely to
be responsible for the improvement in the uremic platelet defect
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row can respond only at a subnormal rate, at best with a twofold
increase [106]. In patients not dependent on transfusions, iron
stores were maintained relatively easily with oral iron; the
demand for iron by the erythroid cells was low. Under these
circumstances, iron stores are best quantified with the serum
ferritin level and not the serum iron or percentage of saturation
of transferrin [1051 (as long as infection or severe inflammation
is not present). With rHuEpo stimulation, however, the ery-
throid marrow responds more than two- to threefold, as deter-
mined by ferrokinetic studies [26, 107], so that a state of relative
iron deficiency can develop. This state is defined as a transferrin
saturation below 20%, a normal serum ferritin level, and a
temporary decrease in rHuEpo-induced reticulocytosis [26, 38].
It is postulated that the erythroid marrow avidly removes iron
from the two binding sites on circulating transferrin at a rate
exceeding the ability of the reticuloendothelial cell to release
iron to transferrin.
Hyperparathyroidism, especially osteitis fibrosa, can inter-
fere with erythropoiesis, as evidenced by the improvement in
anemia in some dialysis patients after subtotal parathyroidec-
tomy [108], and by the blunted effectiveness of rHuEpo in
patients with severe hyperparathyroidism [109]. The quantita-
tive importance of the latter effect awaits further study. It is
marrow fibrosis, as judged by bone biopsy, and not elevated
PTH levels per Se, that correlates best as a predictor of
erythropoiesis after subtotal parathyroidectomy [1081. This
finding suggests that marrow fibrosis limits erythroid marrow
expansion from Epo.
Aluminum excess produces a non-iron-deficient microcytosis
[110, 111], which can aggravate the anemia. Treatment of the
aluminum excess with weekly injections of deferoxamine re-
sults in an increase in red-cell volume within 3 months and in
eventual improvement in the anemia [321. What role aluminum
excess plays in the absence of microcytosis awaits further
study. Using a deferoxamine stimulation test, Casati et a! [28]
and Van Wyck and colleagues [112] demonstrated that alumi-
num excess results in a modest blunting of the erythroid-
stimulating effects of rHuEpo. But the aluminum excess does
not interfere with the efficacy of rHuEpo at doses of 150 and 300
U/kg, 3x/wk. Because hemodialysis patients with non-iron-
deficiency microcytosis have been excluded from studies with
rHuEpo to date, it is not clear what practical influence, if any,
aluminum excess has on rHuEpo effectiveness.
Hypersplenism can aggravate the hemolysis and should be
suspected in any patient with a palpable spleen, leukopenia,
thrombocytopenia, and increasing transfusion requirements.
Splenectomy usually is beneficial for patients in whom
51chromium-labeled red-cell studies disclose a markedly short-
ened red-cell survival and in whom there is a 2:1 or greater
sequestration of red cells in the spleen as compared with the
liver [113]. The causes of hypersplenism are probably multifac-
tonal and include chronic hepatitis [891, transfusion-induced
hemosiderosis [90], marrow fibrosis from severe hyperparathy-
roidism [114], silicone exposure [115], and other causes of acute
hemolysis [116]. Although the patient under discussion had
marked splenomegaly, isotope-sequestration studies failed to
demonstrate significant red-cell entrapment, and red-cell sur-
vival was not markedly shortened.
Folate deficiency, acute or chronic hemolytic conditions,
acute or chronic blood loss, and creation of the anephric state
all can aggravate the anemia of chronic renal failure. Because
patients' appetites sometimes increase when anemia is cor-
rected, adequate oral intake of folate-containing foods will
probably easily compensate for the folate lost via dialyzer
diffusion [117]. Because uremic anephric patients respond as
well to rHuEpo as do uremic patients whose kidneys are in
place [26], the criteria for nephrectomy could change in the
future. Severe hemolysis or severe blood loss obviously can
overcome the erythroid marrow's ability to compensate
acutely, even with rHuEpo therapy, and both these mecha-
nisms should be considered in any patient in whom a stable
hematocrit suddenly drops, whether or not rHuEpo is being
given. The only patient treated with rHuEpo who continued to
require transfusions in the U.S. multicenter clinical trial had
chronic, active gastrointestinal bleeding [29].
Generally, injections of rHuEpo have been well tolerated.
Flu-like or other transitory symptoms occasionally occur after
the injection. To date, no antibodies to rHuEpo have been
detected in the serum of more than 500 patients receiving
rHuEpo three times weekly for up to 2 years [38].
An increase in the red-cell mass to normal or nearly normal
levels can create hemodynamic and other consequences for the
patient with renal failure. Hypertension is aggravated in 30% to
50% of patients during the period that the hematocrit is rising
[25, 29, 38] and requires careful medical control. Hemodynamic
studies indicate that peripheral vascular resistance increases
with a rising red-cell mass, whether induced by transfusion
[118] or rHuEpo [119]; this change might explain the rise in
blood pressure. Of our 68 patients who responded to rHuEpo,
6 experienced grand mal seizures; in 3, the seizures occurred
during the first 3 months of rHuEpo therapy when the hemato-
crit was rising and were associated with a sudden rise in blood
pressure (132/84 to 198/112mm Hg in one patient). Two of these
3 patients, plus the other 3, continue to receive rHuEpo and
have maintained a hematocrit level of 35 without any recur-
rence in seizures. Winearls et a! also reported that a seizure
occurred in one of their 10 patients [25]. Hypertension and
seizures are relatively common in patients with chronic renal
failure, whether or not they are being treated with dialysis. I
suspect that for some patients, particularly those who have had
severe anemia for a long time, the sudden hemodynamic
changes caused by a relatively rapid rise in red-cell mass can
contribute to the worsening hypertension and to the lowered
seizure threshold. Dialyzer clearance for creatinine is signifi-
cantly less at normal hematocnit levels than at hematocrits of
less than 22 [120]. However, no increase in predialysis creati-
nine or BUN levels were reported in the U.S. multicenter
clinical trial with rHuEpo [29]. Appetites improve, and our
dietitians at the Northwest Kidney Center have documented
increases in potassium, sodium, and protein intake. Hyperka-
lemia can become a problem in some patients [26, 28]. There-
fore, in selected patients more dialysis, Kayexalate, or dietary
counseling may be required. An increase in vascular access
clotting has been reported [28], but this was not a significant
problem in the U.S. multicenter clinical trial [29].
Implications for the future
Management of the anemia of chronic renal failure and
treatment of the patient with chronic renal failure will change as
a result of rHuEpo therapy [38]. Recombinant human Epo can
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prevent the anemia and its complications if patients with
progressive renal failure can be identified and treated when
their hematocrit falls below 30. For dialysis patients, transfu-
sions should no longer be required except when sudden, acute
bleeding occurs. Theoretically, autologous transfusions could
be provided for planned, major surgery. Androgen therapy will
no longer be necessary. Complications from transfusions most
likely will be eliminated and iron overload will no longer
develop. Instead, maintaining adequate iron stores for optimal
erythropoiesis will be the major challenge, because all hemodi-
alysis patients will require supplemental iron to compensate for
their fixed dialyzer blood losses. Many patients have gastroin-
testinal intolerance to oral iron, and at least 11% develop
anaphylactic reactions to iron dextran [121]; iron deficiency
therefore could become a major problem in the management of
the hemodialysis patient and either will reduce the effectiveness
of rHuEpo and/or will increase the need for and cost of rHuEpo
therapy.
The future management of the patient with chronic renal
failure will be modified by the fact that rHuEpo-treated patients
will be healthier before beginning dialysis, and hopefully they
will not lose their employment because of fatigue. Some pa-
tients will continue to feel healthy despite very low endogenous
creatinine clearance values, and criteria for initiating dialysis
could change. Indeed, it might be difficult to convince some
patients that they need dialysis.
The impact of rHuEpo on the health of patients with chronic
renal failure should be substantial. Undoubtedly as more expe-
rience is gained in the treatment of the anemia with rHuEpo, the
pathophysiology of the anemia and the consequences of the
anemia in renal failure should be better elucidated.
Questions and answers
DR. JAMES BOURDEAU (Division of Nephrology, Michael
Reese Hospital/University of Chicago, Chicago, Illinois):
When recombinant human erythropoietin becomes available for
clinical use, how much will it cost?
DR. ESCHBACH: I hope that the U.S. Food and Drug Admin-
istration will approve rHuEpo for clinical use in dialysis pa-
tients by late 1988 or early 1989. AMGen, who produces the
rHuEpo used in the multicenter U.S. clinical trial, has yet to
reveal what the cost will be. My hope is that rHuEpo will be
accessible to all who can benefit from it. The End-Stage Renal
Disease Program of Medicare probably will pay for it, but how
it is paid for and how those without supplemental insurance will
pay for it is not clear to me. If the Health Care Financing
Administration (HCFA) includes the cost of rHuEpo in the
dialysis composite rate, I doubt that dialysis centers would be
able to provide adequate amounts of rHuEpo and still receive
adequate reimbursement for their dialysis costs. Hopefully, the
HCFA will reimburse centers for the cost of rHuEpo, as it now
does for blood transfusions and intravenous iron dextran. The
intent of the original legislation that created the End-Stage
Renal Disease program was to provide Medicare funds to
rehabilitate patients who have chronic renal failure. Because
rHuEpo should significantly enhance patient rehabilitation, it
will be important that the End-Stage Renal Disease Program
help to ensure that access to rHuEpo not be an issue.
DR. FREDRIC COE (Director, Joint University of Chica go/Mi-
chael Reese Hospital Program in Nephrology): Is hypertension
from rHuEpo different than the routine volume-expansion
hypertension that is said to account for the vast majority of
hypertension in dialyzed patients?
DR. ESCHBACH: Yes, I believe it is different. Twenty years
ago, Neff and colleagues studied cardiac output and peripheral
vascular resistance in 6 anemic hemodialysis patients before
and after correcting the anemia with red cell transfusions [118].
Peripheral vascular resistance was low when the hematocrit
was 20, so they postulated that anemia led to vasodilation.
When the hematocrit was increased to 40 by increasing red-cell
mass with red-cell transfusions, while controlling plasma vol-
ume with dialysis, peripheral vascular resistance increased
significantly and hypertension was accentuated, even though
cardiac output was decreased from baseline elevated levels. On
the other hand, extracellular volume overload is common in the
dialysis patient and is known to contribute to hypertension.
Maintaining a euvolemic state with adequate dialysis ultrafiltra-
tion often, but not always, maintains a normal blood pressure.
Most patients treated with rHuEpo who have become more
hypertensive when their hematocrit rises above 30 have not
developed extracellular volume overload, although it always
must be ruled out. In our patients, serial chest x-rays have
failed to document pulmonary congestion, and heart sizes even
can diminish. Radioactive chromium red-cell-mass studies in-
dicate that plasma volume decreases as the hematocrit rises,
without an increase in whole-blood volume. Hypertension has
developed in anephric patients whose anemia is corrected with
rHuEpo [261; therefore renal renin production probably is not a
factor in the genesis of this hypertension. Approximately 80%
of patients with progressive renal failure develop hypertension.
We thought that hypertension often was controlled by dialysis
because of better sodium control through ultrafiltration. I
believe that mechanism is important, but I wonder whether the
anemia-induced vasodilation also contributes to a lowering of
blood pressure. If it does, then correcting the anemia should
reverse the process. Some of the rHuEpo-treated patients who
became hypertensive eventually became normotensive when
they adjusted to the non-anemic state.
DR. BOURDEAU: Has blood viscosity been measured prior to
and following administration of rHuEpo? Is it possible that the
increasing hypertension is related to an increase in blood
viscosity?
DR. ESCHBACH: Blood viscosity increases in anemic hemo-
dialysis patients as the hematocrit rises from rHuEpo therapy
[122]. The increase is not any greater than what would be
observed in an anemic individual with normal renal function
whose hematocrit returns to normal as a result of iron or other
hematinic therapy, however. Increasing blood viscosity per se
is not the cause of the increasing arterial pressures observed
during acute correction of anemia with rHuEpo.
DR. GARY TOBACK (Section of Nephrology, Mitchell Hospi-
tal, University of Chicago): I want to ask about the pathophy-
siology of anemias in patients with chronic inflammatory dis-
eases. You provided data indicating that the response of the
marrow to a fixed dose of recombinant erythropoietin was
reduced in patients with inflammatory disease. What abnormal-
ity occurs in the marrow that leads to this reduced responsive-
ness to erythropoietin?
DR. ESCHBACH: The decreased responsiveness of the ery-
throid marrow to rHuEpo in the presence of an infection or
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inflammatory state (such as after surgery) is not a direct marrow
abnormality. Rather, the defect is a block at the reticuloendo-
thelial cell that prevents the release of iron to circulating
transferrin, thus limiting the amount of iron available for
hemoglobin synthesis. We do not have enough experience to
know whether excessive rHuEpo can overcome this inflamma-
tory block. A recent study did suggest that rHuEpo could
correct the mild anemia in patients with rheumatoid arthritis
[1231, but the response was slower than that observed with
comparable doses used in hemodialysis patients. Whether the
anemia occurring with other inflammatory states can be cor-
rected with rHuEpo, and at what dose, remains to be deter-
mined.
DR. TOBACK: As you mentioned, a considerable body of
evidence suggests that the serum of patients with end-stage
renal disease contains inhibitors of erythropoiesis. Your pre-
sentation indicated that provision of recombinant erythropoie-
tin can overcome this inhibition, and you surmised that the
inhibitors were not the major determinant of the anemia. I
would like to suggest an alternative hypothesis concerning
these findings. Could it be that in anemic patients, who have or
don't have renal failure, hypoxia is perceived by a specific set of
cells that release one or more inhibitors that act on CFU-E cells
to block erythroid development? Exogenous erythropoietin
acting on the same target cells could overcome this inhibitory
effect, stimulate erythropoiesis, increase red-cell mass, amelio-
rate cellular hypoxia, and thereby shut off production of the
inhibitor. In this hypothesis, a circulating inhibitor still could
mediate the anemia, and its effect could be overcome by
erythropoietin, as you observed. Although the inhibitors would
have to be identified to test this hypothesis, I would be
interested in your thoughts.
DR. ESCHBACH: To my knowledge, production of neither
murine nor canine erythroid marrow cells is inhibited when
anemic sera from subjects without renal failure is added to these
cultured erythroid cells in the presence of erythropoietin. In the
intact organism without renal disease, anemia or hypoxia leads
to an appropriate erythropoietin response with subsequent
erythroid stimulation. Segal and colleagues failed to detect any
inhibition of autologous CFU-E cell growth when anemic,
predialysis serum was incubated in the presence of erythropoi-
etin [59]. On teleologic grounds, I do not understand why
hypoxia per se would result in the release of inhibitors to
CFU-E growth. There is no evidence that hypoxia results in the
release of CFU-E inhibitors.
DR. JORDAN J. COHEN (Dean of Medicine, State University
of New York at Stony Brook, Stony Brook, New York): There is,
of course, another way that a putative inhibitor might play a
role in the anemia of chronic renal disease. Given the poor
correlation between the degree of renal insufficiency and the
degree to which the hematocrit falls in this patient population,
could something be inhibiting the release of erythropoietin by
the kidney rather than be inhibiting the effect of the hormone on
the bone marrow? Why should a patient with relatively mild
renal insufficiency, who has only a moderate reduction in renal
size, develop anemia if major inhibitors of the bone marrow are
not present and if erythropoietin production is normally deter-
mined by renal mass?
DR. ESCHBACH: I know of no evidence that renal mass
correlates with the ability of the kidney to produce erythropoi-
etin. Rather, the responsiveness of the renal cell (presumably
the peritubular capillary endothelial cell [91, 92]) to hypoxia is
regulated at the cellular level by factors that we do not yet
understand. These cells are adjacent to the proximal tubule.
Does tubular function relate to Epo secretion? If so, how? The
term "inhibitor" has been used to connote a product of tissue
metabolism not excreted by the kidney. If you are referring to
an inhibitor in a broader sense, then there might be substances
or cellular mechanisms that interfere with the usual hypoxic
stimulus to these cells. On the other hand, we have no infor-
mation about how these cells sense the existence of hypoxia, so
there also might be mechanisms that accentuate the cells' Epo
response to hypoxia. Hopefully, scientists soon will be able to
answer these questions.
DR. CARL POCHEDLY (Department of Pediatrics, Michael
Reese Hospital): What are the long-term adverse side eftects of
erythropoietin? Has it been used extensively in children?
DR. ESCHBACH: Recombinant human erythropoietin has been
given three times weekly for more than 2 years to 18 patients in
Seattle who originally were enrolled in the phase-I clinical trial.
Routine blood and serum analysis, clotting paraiheters, chest
x-rays, electrodardiograms, and clinical observation and exam-
ination have revealed no direct side effects from the recombi-
nant hormone. No antibodies to rHuEpo have been detected in
the serum of these patients. The only adverse effects appear to
be related to correction of the anemia, especially a rising blood
pressure in some patients. Seizures rarely occur. These effects
occur mainly during the first 3 to 4 months, when the hematocrit
is rising relatively rapidly. It remains to be determined whether
these adverse effects will occur less frequently if the anemia is
corrected over a longer period. It is interesting, though, that
seizures have not recurred in patients continuing to receive
rHuEpo. Patients do not seem to be refractory to rHuEpo after
they initially respond. To answer your second question, the
United States clinical trials with rHuEpo have not involved
children. But the response of a 7-year-old, transfusion-depen-
dent, iron-overloaded hemodialysis patient from Marburg,
West Germany, to rHuEpo was similar to that reported in
adults [124].
DR. SERAFINO GARELLA (Associate Chairman of Medicine,
Michael Reese Hospital): One of the strongest pieces of evi-
dence suggesting that inhibitors to erythropoiesis exist in pa-
tients with renal failure is that the erythropoietin level in some
of these patients is, if not normal for the degree of anemia, at
least close to normal. Because patients with renal failure
demonstrate a shortened red-cell survival as well as decreased
production rates, would they not require higher levels of
erythropoietin to maintain a given hematocrit? If the answer is
positive, then finding "normal" levels of erythropoietin in
patients with the anemia of renal disease would be evidence in
favor of the existence of inhibitors.
DR. ESCHBACH: If uremic inhibitors acted against the produc-
tion of renal erythropoietin, it might be one explanation for your
hypothesis. However, inadequate production of erythropoietin
by the diseased kidney regardless of the underlying disease,
also can account for the findings of "normal" levels of serum
erythropoietin in patients with chronic renal failure and anemia.
DR. KAI LAU (Director, Renal Division, Michael Reese
Hospital): To use the apparently sluggish response of patients
with renal disease to exogenous erythropoietin as evidence for
144 Nephrology Forum: Recombinant eiythropoietin in chronic renal failure
the presence of bone-marrow inhibitors, one would need to
know the dose-response curve of normal subjects. Do we have
such data?
DR. ESCHBACH: Not at this time. We cannot rule out the
presence of erythropoietic inhibitors in renal failure until we
study the effect of rHuEpo in normal subjects and compare the
erythropoietic response with the response to similar doses of
rHuEpo given to hemodialysis patients.
DR. DAVID BUSHINSKY (Section of Nephrology, Mitchell
Hospital, University of Chicago): Have you used phlebotomy
in conjunction with increased amounts of erythropoietin to
accelerate the rate of iron loss to relieve some of the compli-
cations of iron overload?
DR. ESCHBACH: Your suggestion is valid and has been tried
[124]. The issue is whether iron overload needs to be corrected
more rapidly than using rHuEpo without concomitant phlebot-
omy. The relationship between the serum ferritin level and
organ dysfunction secondary to iron overload has not been
established. Patients with serum ferritin levels greater than 5000
g/ml (in the absence of active inflammation) are at increased
risk of developing organ dysfunction from iron [85]. Our expe-
rience suggests that serum ferritin levels fall 50% within one
year of the administration of effective doses of rHuEpo coupled
with the usual dialyzer blood losses and without concomitant
phlebotomy. Therefore I believe that only occasionally will
patients require supplemental phlebotomy to manage the iron
overload.
Da. BUSHINSKY: Knowing the pool size of erythropoietin and
its degradation rate, one could calculate the production rate in
normal individuals and compare it with the amount of exoge-
nous erythropoietin needed to achieve the same serum level.
You could answer many of the questions relating to possible
inhibition of erythropoiesis in uremia by determining whether
exogenous administration equals endogenous production. Has
this approach been attempted?
DR. ESCHBACH: No. Exogenous erythropoietin in the form of
rHuEpo has been given only as bolus injections intravenously
or subcutaneously 3 times weekly. This regimen does not
achieve steady-state conditions.
DR. COHEN: Do we know what level of erythropoietin is
achieved in the circulation of your patients? They are clearly
not in a steady state, given the episodic doses of rHuEpo they
receive, but can one estimate the average circulating level of
erythropoietin and compare it with what one sees in nonuremic
patients who are anemic for other reasons?
DR. ESCHBACH: The serum levels of rHuEpo depend on the
dose and the route of administration. In one patient given 15
U/kg intravenously, the serum level increased from a baseline
value of 17 mU/mi to 260 mU/mi one hour later and declined to
52 mU/mi by 24 hours. In another patient, given 150 U/kg
intravenously, the serum level increased from a baseline of 22
mU/mi to 2300 mU/mi one hour later and declined to 322 mU/mi
by 24 hours. Larger doses will result in even higher circulating
levels of rHuEpo. When 150 U/kg was injected subcutaneously
into another patient, the serum erythropoietin level increased
slowly from a baseline value of 19 mU/mi to 192 mU/ml by 24
hours [961. These values are not steady state and therefore are
impossible to compare with levels of serum erythropoietin
randomly measured from nonuremic patients with anemia.
Pharmacokinetic studies with rHuEpo have yet to be performed
in normal individuals.
DR. STUART SPRAGUE (Renal Fellow, Joint University of
Chicago/Michael Reese Hospital Program in Nephrology): It
appears that one can adjust the dose of rHuEpo to achieve
whatever hematocrit is desired in an individual patient. Regard-
ing the side effects associated with rHuEpo therapy, such as
high blood pressure, seizures, and the need for more dialysis,
what information is available regarding the optimal hematocrit
in these patients? Is a hematocrit of 30% or 35% as good as 40%
in improving a patient's functional status?
DR. ESCHBACH: The adverse effects of hypertension and
seizures appear to be a function of the rate at which the
hematocrit rises during the acute treatment period. Patient
performance probably depends on the final hematocrit level,
but exercise-tolerance studies are required to determine what
hematocrit level is optimal. It is not known whether a higher
hematocrit level will be associated with a higher incidence of
hypertension, or whether hypertension will be more difficult to
control. Preliminary data suggest that the incidence of seizures
is more a function of the rapid rise in hematocrit (and blood
pressure) during the acute treatment period, and is not a
function of the hematocrit itself. We have no data suggesting
that patients with hematocrits maintained at 40% will require
more dialysis than will patients with hematocnts of 30%.
DR. SATISH KUMAR (Renal Fellow, Joint University of Chi-
cago/Michael Reese Hospital Program in Nephrology): Are the
erythropoietin-producing endothelial cells morphologically dis-
tinguishable from other endothelial cells?
DR. ESCHBACH: These cells have been located in the anemic
mouse kidney by silver grains adhering to their surfaces using
an in-situ hybridization technique with a 35S-labeled mouse Epo
genomic probe. Approximately 20% to 50% of the cortical
interstitial endothelial cells do not adhere to the probe [125],
and I don't believe that routine histology can distinguish
between those cells that do and do not react with the probe.
DR. COHEN: If you had an unlimited supply of rHuEpo, and
cost was not a factor, when in the course of the development of
progressive renal failure would you recommend that it be given
initially?
DR. ESCHBACH: I'd recommend that it be administered when
the hematocrit decreases to below 30%. I base this opinion on
the subjective responses of anemic patients with progressive
renal failure who have been treated with rHuEpo. Future
detailed objective studies utilizing exercise-tolerance testing
might modify that recommendation.
DR. PAUL SACKS (Renal Fellow, Joint University of Chica-
go/Michael Reese Hospital Program in Nephrology): In your
discussion, you touched on the increased incidence of dialyzer
clotting as one of the adverse complications of rHuEpo therapy.
Others have included an increased incidence of arteriovenous
fistula clotting with this form of therapy [25], Using your
patients as their own controls, what is the excess incidence of
vascular-access clotting that can be attributed to rHuEpo
therapy? Is there a direct correlation between this complication
and the increase in hematocrit?
DR. ESCHBACH: The results of the multicenter trial with
rHuEpo failed to document an increased incidence in vascular-
access clotting when the target hematocrit of 35% was obtained
and maintained [29]. Because most hemodialysis patients have
Nephrology Forum: Recombinant erythropoietin in chronic renal failure 145
either a Gore-Tex or bovine arteriovenous graft, both of which
tend to clot once or twice yearly (in contrast with an autogenous
fistula), and because graft clotting is quite episodic, it is difficult
to know whether a rising hematocrit that may be associated
with improved hemostasis [103, 104] results in increased graft
clotting. We have analyzed the data from our patients. Of 68
patients treated with rHuEpo for 12 to 27 months, clotting
occurred 3 or more times in the vascular accesses of only 8
patients. Clotting occurred only in Gore-Tex or bovine grafts,
and it was not necessarily related to an acute rise in the
hematocnt.
DR. SATISH KATHPALIA (Attending Nephrologist, Michael
Reese Hospital): You mentioned that rHuEpo has been used to
treat bleeding in uremic patients. How does this therapy correct
bleeding?
DR. ESCHBACH: A prolonged bleeding time is the major
manifestation of platelet dysfunction in uremia. Casati showed
that the bleeding time decreases toward normal in anemic
hemodialysis patients when the hematocrit increases to over
30% with rHuEpo therapy [104]. This observation suggests that
anemia might affect platelet function. One theory is that anemia
increases the shear stress on the endothelial cell and results in
an increase of prostaglandin '2production, which in turn leads
to increased vascular friability and bleeding. Correcting the
anemia thus would indirectly decrease PG!2 activity.
DR. MARK RICHTER (Section of Nephrology, Mitchell Hos-
pital, University of Chicago): As you have pointed out, patients
with chronic renal failure treated with rHuEpo feel better, and
many of the symptoms we have attributed to uremia in fact
might be related to anemia. Long-term studies will determine
whether this translates into improved morbidity and mortality
rates in our patients. Our dialysis-prescribing habits are in large
part based on the results of the National Cooperative Dialysis
Study [126]. In that study, patients had a mean hematocrit of
20.0% to 27.1%. Do we need to rethink our entire concept of the
adequacy of dialysis now that our patients will have higher
baseline hemoglobin levels? Isn't it possible that patients with
higher hemoglobin levels might do quite well with less dialysis?
DR. ESCHBACH: Theoretically I believe you are correct;
patients with nearly normal hemoglobin levels could tolerate
higher serum creatinine and urea nitrogen levels. But many
patients tend to eat more after rHuEpo therapy and thus have a
tendency to have higher serum potassium levels [28] and to
consume more sodium-containing foods [381. These patients
might require more, not less, dialysis. Until carefully controlled
studies indicate that dialysis patients with nearly normal hem-
atocrit levels can do as well with less dialysis, I would caution
against shortening dialysis times, except possibly with high-flux
membranes. More experience is required for us to know how
patients with nearly normal hematocrits tolerate high-flux dial-
ysis.
DR. POCHEDLY: There are two uses of rHuEpo that you
didn't mention. These are its use in sickle-cell disease and also
its use by athletes to increase their stamina. What do you think
about the use of rHuEpo in these situations?
DR. ESCHBACH: The clinical trials using rHuEpo have not
included anemic patients with sickle-cell disease; therefore,
there has been no experience in their treatment. In patients with
sickle-cell disease, rHuEpo stimulates fetal hemoglobin produc-
tion [127] and probably improves the anemia. It is unknown at
this time whether such an improvement would result in an
increase in sickling and hemolytic crises.
Blood "doping," that is, erythrocyte reinfusion, increases
exercise tolerance [128], and I understand the technique is
employed by some athletes to increase their stamina. I suspect
that rHuEpo also will be used surreptitiously in place of blood
doping. Unless baseline hematocrit levels were known on all
athletes, it would be difficult to monitor the misuse of rHuEpo
in athletes, because the reticulocyte count would return to
normal within 7 days after intravenous rHuEpo injections are
withheld. Because some athletes will think, "If a little is good,
more should be better," some could attain a very high hema-
tocrit, which could be associated with an increased frequency
of vascular complications.
DR. NIC0LA0s E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston): Improvements, in the
sense of general well-being and exercise tolerance, are antici-
pated following rHuEpo treatment. Have such changes been
documented using quantitative methods?
DR. ESCHBACH: A quality-of-life questionnaire has been
completed by patients before rHuEpo therapy, immediately
after the target hematocrit was attained, and 3 to 6 months later.
Although the details of this questionnaire have not been pub-
lished, preliminary data available at the December 1987 meeting
of the American Society of Nephrology indicated significant
improvement in various facets of quality of life when the anemia
is corrected [29]. Three groups have studied exercise tolerance
by using a bicycle ergometer to assess oxygen utilization
[129—131]. In general, oxygen utilization increases as the ane-
mia improves, but not necessarily to normal. It is unclear
whether correction of the anemia with rHuEpo will completely
normalize oxygen utilization in the patient on chronic hemodi-
alysis.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesely Hospital, Newton, Massachusetts): What will be the
financial cost to the patient, and ultimately to society, if a
substantial percentage of patients with end-stage renal disease
begin to receive rHuEpo routinely?
DR. ESCHBACH: At this time, I do not know what the cost of
rHuEpo therapy will be. It is hoped that the kidney-Medicare
program eventually will pay for rHuEpo, so the cost ultimately
will be society's. I suspect that approximately 75% of dialysis
patients will benefit from rHuEpo therapy. It will be expensive,
but its relative cost will be less because of the savings that result
from correcting the anemia. For instance, the direct costs of
blood transfusions and androgens (used to stimulate erythro-
poiesis) will be eliminated. The indirect costs of transfusions
and androgens also will be eliminated: complications from
hepatitis B infection; non-A, non-B hepatitis and other transfu-
sion-related infections; iron overload; HL-A sensitization pre-
venting a kidney transplant (which is more cost effective than
dialysis); and side effects from androgens. Patients will be
healthier and, I suspect, will require fewer costly stays in the
hospital. I anticipate that eventually more patients will be
rehabilitated, employed, and thus will contribute to society and
pay taxes.
Reprint requests to Dr. J. Eschbach, Division of Hematology,
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